IRB Barcelona Leads MD4SB Project to Advance Dynamic Representation in Structural Biology

In the ever-evolving landscape of biomedical research, the advent of molecular dynamics simulations has heralded a new era of insight into the dynamic behavior of biological macromolecules. Yet, despite the immense volumes of data generated by these simulations, much remains untapped due to the lack of adequate infrastructure for storage, sharing, and reuse. Addressing this critical gap, the MD4SB (Molecular Dynamics for Structure-based Biology) project emerges as a visionary initiative poised to revolutionize how molecular dynamics data is integrated, managed, and exploited across Europe.

Set to launch in September 2026, MD4SB is a collaborative endeavor funded with €10 million under the Horizon Europe program and coordinated by the Institute for Research in Biomedicine (IRB Barcelona). The project unites 25 partners spanning eight countries, encompassing academic institutions, European research infrastructures, supercomputing centers, as well as biotech and pharmaceutical companies. By doing so, it offers a multidisciplinary approach aimed at transforming fragmented computational efforts into a coherent, accessible, and reusable resource for the scientific community.

At the core of MD4SB is the establishment of an innovative infrastructure designed to dynamically describe biological macromolecules through molecular dynamics data. Unlike traditional structural biology methods that primarily capture static snapshots of molecules, molecular dynamics simulations reveal the conformational flexibility and temporal evolution of proteins and nucleic acids. This dynamic information is crucial for fully understanding molecular function, interaction mechanisms, and especially drug binding processes, thus providing a more nuanced picture for drug discovery initiatives.

MD4SB builds on the foundations laid by the Molecular Dynamics Data Bank (MDDB), which pioneered a distributed platform adhering to the FAIR principles—making data Findable, Accessible, Interoperable, and Reusable. The project advances this concept by integrating molecular dynamics data within three major European Research Infrastructures: Instruct-ERIC, which specializes in structural biology; ELIXIR, focused on life sciences data management; and EU-OPENSCREEN ERIC, a chemical biology and compound screening infrastructure. This integration ensures that molecular dynamics data becomes a shared asset rather than an isolated entity confined to individual laboratories.

Leveraging the capabilities of Europe’s largest supercomputing centers—specifically the Barcelona Supercomputing Center (BSC-CNS), CINECA in Italy, and the Jülich Supercomputing Centre (JSC)—MD4SB provides the computational muscle necessary for processing, storing, and analyzing massive datasets. These centers, combined with emerging AI Factories, will enable cutting-edge analysis pipelines that augment traditional molecular dynamics approaches with artificial intelligence, thus enhancing the extraction of biologically meaningful patterns from complex simulations.

One of the landmark objectives of MD4SB is to catalyze early drug discovery by enabling scientists to visualize the dynamic movements of proteins and other biomolecules that are often invisible in static crystal structures. Molecular dynamics simulations can reveal transient binding pockets and allosteric sites, which are pivotal for designing new therapeutic compounds with higher specificity and efficacy. By facilitating access to these insights within existing infrastructures, MD4SB aims to speed up the identification of drug candidates and reduce costly experimental failures.

Industry engagement lies at the heart of MD4SB’s strategy. Leading pharmaceutical companies such as Almirall and Sanofi are involved as associate partners, providing critical feedback to ensure that the developed platform not only serves academic research but also aligns with industrial requirements. The involvement of Nostrum Biodiscovery—a biotech spin-off from IRB Barcelona and BSC-CNS—further exemplifies the project’s commitment to bridging the gap between fundamental research and commercial application by easing the transition of innovations into practical tools.

Dr. Modesto Orozco, coordinator of MD4SB and head of the Molecular Modelling and Bioinformatics laboratory at IRB Barcelona, highlights the transformative potential of this initiative: “For the first time on a European scale, MD4SB will merge structural biology, molecular dynamics, artificial intelligence, and drug discovery into a seamless ecosystem. Our vision is to democratize molecular dynamics, making it a common capability accessible to researchers across disciplines.”

The strategic approach of MD4SB entails the seamless coupling of three complementary research infrastructures, encompassing the full spectrum of biomedical research phases: from structural protein characterization, data stewardship and interoperability, to chemical biology screening for therapeutic potentials. This holistic integration enables unprecedented collaborative workflows, where data generated in one context can be analyzed, reanalyzed, and repurposed across diverse scientific domains.

Central to the success of MD4SB will be its adherence to data standards and protocols that guarantee FAIR compliance, ensuring that the vast repositories of molecular dynamics simulations remain discoverable and usable well beyond the lifespan of individual projects. This commitment is indispensable in preventing the loss of valuable computational endeavors, promoting reproducibility, and fostering innovation driven by shared resources.

By significantly expanding the accessibility and applications of molecular dynamics data, MD4SB promises to address a longstanding bottleneck in the life sciences: the disconnect between data generation and data reuse. The project envisions a future where high-quality, large-scale molecular simulations are no longer restricted to elite research groups but are a universally available asset, fueling discoveries in biology, chemistry, and medicine.

The timeline for MD4SB spans four years, during which it will not only develop and deploy the integration platform but also benchmark its utility through real-world case studies involving both academic and industry partners. Through this collaborative validation process, the project expects to establish best practices, refine analytical tools, and build a sustainable infrastructure that institutionalizes molecular dynamics as a pillar of modern biomedical research.

In conclusion, MD4SB heralds a transformative chapter for the European research ecosystem by converging molecular dynamics with cutting-edge computational resources and artificial intelligence within a unified framework. Its success will empower scientists to decode the dynamic complexity of biological molecules at an unprecedented scale, accelerating drug discovery pipelines and fostering interdisciplinary collaboration in the era of data-driven bioscience.

News Publication Date: June 17, 2026

Web References:

• MD4SB project official website (to be launched)
• Horizon Europe funding portal
• IRB Barcelona: https://www.irbbarcelona.org/